How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,098 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Is there any evidence for DEXA scanning in patients on depo provera

Is there any evidence for DEXA scanning in patients on depo provera Is there any evidence for DEXA scanning in patients on depo provera - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence for DEXA scanning in patients on depo provera The Faculty of Family Planning and Clinical Effectiveness Unit (FFPRHC) answered a query on the most recent advice concerning bone mineral density and the use of depot-medroxyprogesterone acetate

2010 TRIP Answers

22. What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i

to use additional contraception or avoid sex for the next 7 days. The need for emergency contraception should be assessed individually.” In December 2009 TRIP Answers answered a similar question as to whether the duration of repeat depo provera had been extended to thirteen and a half weeks (2). We have provided a link to the answer below. 1. 2. Answered 28 April 2010 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK. (...) What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even i What is the latest time that depo medroxyprogestogen acetate can be given? It is usually 12 weeks + 5 days. I believe there is some evidence that it can be given at 14 weeks after last depo and even if unprotected SI has occurred emergency contraception is not indicated. - Trip Database or use

2010 TRIP Answers

23. Guidelines for Protecting the Front Line: COVID 19 Day-to-Day Questions

.) Injections that can be administered within a windowed timeframe (e.g., 1-3 months, 3-6 months, etc.) should be postponed to later within that window, whereas injections that are part of a regular schedule should be prioritized to maintain continuity of care. In cases where injectable medications can no longer be administered (e.g., B12, Depo-Provera, Prolia, antipsychotics, etc.), pharmacists can consider switching formulations (i.e., injection to oral tablet), using alternative medications or modifying

2020 Covid-19 Ad hoc guidelines

26. Treatments for seizures in catamenial (menstrual-related) epilepsy. Full Text available with Trip Pro

with regular menses, and complete cessation of menstruation using synthetic hormones (e.g. medroxyprogesterone (Depo-Provera) or gonadotropin-releasing hormone (GnRH) analogues (triptorelin and goserelin)) in women with irregular menses.Catamenial epilepsy and seizure exacerbation is common in women with epilepsy, and may have a significant negative impact on quality of life. Women may not be receiving appropriate treatment for their seizures because of uncertainty regarding which treatment works best

2019 Cochrane

28. Dysmenorrhoea: Scenario: Primary dysmenorrhoea

paracetamol. If the woman does not wish to conceive, consider prescribing a 3–6 month trial of a hormonal contraceptive as an alternative first-line treatment. Monophasic combined oral contraceptive (COC) preparations containing 30–35 micrograms of ethinylestradiol and norethisterone, norgestimate, or levonorgestrel are usually first choice. Oral (desogestrel 75 micrograms), parenteral (Depo-Provera ® or Sayana Press ® , and Nexplanon ® ), and intrauterine progestogen-only (Mirena ® ) contraceptives may

2020 NICE Clinical Knowledge Summaries

29. Contraception - progestogen-only methods

due to method failure. The progestogen-only injectables contain depot medroxyprogesterone acetate (Depo Provera® and Sayana Press®) or norethisterone enantate (Noristerat®). Depo Provera® should be given by deep intramuscular injection every 12 weeks. Sayana Press® should be given by subcutaneous injection every 13 weeks. Noristerat® should be given by deep intramuscular injection every 8 weeks, but is only used for short term use (two injections). Progestogen-only injectables prevent pregnancy

2020 NICE Clinical Knowledge Summaries

30. Contraception - progestogen-only methods: Scenario: Progestogen-only injectables

injectable on day 1–5 of the menstrual cycle. No additional contraception is required. If the progestogen-only injectable is given at any other time in the menstrual cycle: Advise the woman to abstain from sex for 7 days, or continue the existing method for at least 7 days. What types of progestogen-only injectables are available? Three progestogen-only injectables are currently available in the UK: Depot medroxyprogesterone acetate 150 mg (Depo-Provera®) is the most commonly used progestogen-only (...) -only injectable should I recommend? If the woman requires contraception for only a few months (short-term use), consider either: Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®), or Norethisterone enantate (Noristerat®). If the woman requires long-term contraception, consider: Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®). Women may self-administer Sayana Press® after the first injection once they have received training in injection technique

2020 NICE Clinical Knowledge Summaries

34. Breast cancer - managing Family History: Scenario: Breast cancer - managing family history

contraception can be considered? For women with a family history of breast cancer, the following may, therefore, be used without restriction (UKMEC category 1): The copper-bearing intrauterine device (Cu-IUD). For more information, see the CKS topic on . The levonorgestrel-releasing intrauterine system (LNG-IUS, for example, Mirena ® ). For more information, see the CKS topic on . Etonogestrel-only implant (Nexplanon ® ). For more information, see the CKS topic on . Depot medroxyprogesterone acetate (Depo (...) -Provera ® , SAYANA PRESS ® ). For more information, see the CKS topic on . Progestogen-only pill (POP). For more information, see the CKS topic on . Combined hormonal contraceptives (CHC). For more information, see the CKS topic on . Inform women aged over 35 years with a family history of breast cancer that there is an increased risk of breast cancer associated with taking the oral contraceptive pill, given that their absolute risk increases with age. Advice to women up to age 35 years with a family

2018 NICE Clinical Knowledge Summaries

35. Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry

? Radiographic evidence of osteopenia ? Rheumatoid arthritis ? Thyroid disease ? Anyone on a medication associated with development of osteoporosis, including but not limited to the following medications: ? Glucocorticoids (e.g., prednisone, prednisolone, decadron, dexamethasone) – treatment for longer than 3 months ? Phenytoin (Dilantin) – treatment for longer than 3 months ? Heparin – treatment for longer than 1 month ? Depo-Provera injectable contraceptive – long-standing use (longer than 2 years

2018 AIM Specialty Health

37. e-income countries from a provider’s perspective: a systematic review Full Text available with Trip Pro

disaggregated into component costs. However, only the study, conducted in Uganda, specified the type of FP commodity being provided. In that study, provision of condoms in a health centre was the least expensive FP service (US$2.72) while the most expensive FP service was the provision of the injectable contraceptive, Depo-Provera in a hospital (US$5.27). As regards cost drivers of service provision, personnel cost was higher when commodities such as oral pills and Depo-Provera were being provided, while

2020 BMJ global health

38. Oral contraceptives and intrauterine devices as risk factors for breast and cervical cancers: a systematic review Full Text available with Trip Pro

. World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs351/e. Accessed September 2018. Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women’s cancers: a grand challenge in global health. Lancet. 2017;389(10071):847-60. Spevack E. The long-term health implications of depo-provera. Integrat Medi. 2013 Feb;27. Reyes HD, Carlson M, McDonald M, Zhang Y, Dai D, Yang S, et al. The effect of progesterone-containing intrauterine

2020 International Journal of Research in Medical Sciences

40. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary A new formulation of depot medroxyprogesterone acetate (DMPA) for subcutaneous administration (DMPA-SC 104 mg/0.65 ml, Sayana Press) was shown to be as effective as DMPA given by intramuscular administration (DMPA-IM 150 mg/ml, Depo-Provera) for preventing pregnancy. Bone mineral density (BMD) loss and weight gain were similar with both methods (...) of DMPA for subcutaneous administration (DMPA–SC) for use as long-term female contraception, administered every 13 weeks. It is an alternative to DMPA administered by intramuscular injection (DMPA-IM, Depo-Provera) and was launched in the UK in June 2013. DMPA works by inhibiting gonadotrophin secretion, which, in turn, prevents ovulation. This evidence summary is based on 3 trials that evaluated the contraceptive efficacy and safety of DMPA-SC. One of these was a randomised controlled trial

2014 National Institute for Health and Clinical Excellence - Advice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>